- Home
- NUVL vs BDC Comparison
NUVL vs BDC Comparison
Compare NUVL & BDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- BDC
- Stock Information
- Founded
- NUVL 2017
- BDC 1902
- Country
- NUVL United States
- BDC United States
- Employees
- NUVL N/A
- BDC N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- BDC Telecommunications Equipment
- Sector
- NUVL Health Care
- BDC Telecommunications
- Exchange
- NUVL Nasdaq
- BDC Nasdaq
- Market Cap
- NUVL 5.5B
- BDC 4.6B
- IPO Year
- NUVL 2021
- BDC 1993
- Fundamental
- Price
- NUVL $79.49
- BDC $111.57
- Analyst Decision
- NUVL Strong Buy
- BDC Strong Buy
- Analyst Count
- NUVL 11
- BDC 5
- Target Price
- NUVL $112.36
- BDC $130.20
- AVG Volume (30 Days)
- NUVL 420.4K
- BDC 271.5K
- Earning Date
- NUVL 03-04-2025
- BDC 02-06-2025
- Dividend Yield
- NUVL N/A
- BDC 0.18%
- EPS Growth
- NUVL N/A
- BDC N/A
- EPS
- NUVL N/A
- BDC 4.80
- Revenue
- NUVL N/A
- BDC $2,460,979,000.00
- Revenue This Year
- NUVL N/A
- BDC $12.52
- Revenue Next Year
- NUVL N/A
- BDC $4.98
- P/E Ratio
- NUVL N/A
- BDC $23.24
- Revenue Growth
- NUVL N/A
- BDC N/A
- 52 Week Low
- NUVL $61.80
- BDC $80.90
- 52 Week High
- NUVL $113.51
- BDC $131.82
- Technical
- Relative Strength Index (RSI)
- NUVL 43.83
- BDC 38.98
- Support Level
- NUVL $77.84
- BDC $112.89
- Resistance Level
- NUVL $85.21
- BDC $116.11
- Average True Range (ATR)
- NUVL 3.78
- BDC 3.39
- MACD
- NUVL -0.46
- BDC -0.19
- Stochastic Oscillator
- NUVL 12.08
- BDC 36.59
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About BDC Belden Inc
Belden Inc provides signal transmission products to distributors, end-users, installers, and original equipment manufacturers. The firm operates in two segments - Enterprise Solutions and Industrial Solutions. The Enterprise Solutions segment is a provider in network infrastructure solutions, as well as cabling and connectivity solutions for commercial audio/video and security applications. The Industrial Solutions segment is a provider of high-performance networking components and machine connectivity products. It operates in Americas, EMEA and APAC, out of which maximum revenue from Americas.